Shearman & Sterling has advised longtime client Novartis on its $1.2bn (£757m) acquisition of the generic cancer drug business of EBEWE Pharma, reports The Am Law Daily. Corporate partner Harald Selzner, who is based in Duesseldorf, led the firm's team on the deal.Shearman has represented Swiss-based pharma giant Novartis on several previous deals, including its $8.4bn (£5.3bn) acquisition of generic drug makers Eon Labs and Hexal in 2005. Wachtell Lipton Rosen & Katz also advised Novartis on that deal.
May 22, 2009 at 06:49 AM
1 minute read
The original version of this story was published on Legalweek
Shearman & Sterling has advised longtime client Novartis on its $1.2bn (£757m) acquisition of the generic cancer drug business of EBEWE Pharma, reports The Am Law Daily.
Corporate partner Harald Selzner, who is based in Duesseldorf, led the firm’s team on the deal.
Presented by BigVoodoo
Celebrate outstanding achievement in law firms, chambers, in-house legal departments and alternative business structures.
The African Legal Awards recognise exceptional achievement within Africa s legal community during a period of rapid change.
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Lower Manhattan firm seeks a premises liability litigator (i.e., depositions, SJ motions, and/or trials) with at least 3-6 years of experien...
At NJM, a top-rated insurance company, we are seeking an Attorney on our Workers Compensation legal team with between 3 and 5 years of expe...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
